SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 14,600 shares, a decrease of 22.8% from the September 15th total of 18,900 shares. Based on an average trading volume of 54,500 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the company’s stock are sold short.

SOPHiA GENETICS Stock Up 2.4 %

Shares of NASDAQ SOPH traded up $0.08 during trading hours on Tuesday, hitting $3.46. 9,430 shares of the stock were exchanged, compared to its average volume of 71,575. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The firm has a fifty day moving average price of $3.67 and a 200-day moving average price of $4.40. The company has a quick ratio of 4.17, a current ratio of 4.40 and a debt-to-equity ratio of 0.11. The company has a market cap of $226.20 million, a PE ratio of -3.01 and a beta of 1.03.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The business had revenue of $15.81 million for the quarter, compared to the consensus estimate of $17.58 million. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 102.84%. During the same period in the prior year, the firm posted ($0.33) earnings per share. On average, sell-side analysts expect that SOPHiA GENETICS will post -0.95 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on SOPH. Guggenheim started coverage on shares of SOPHiA GENETICS in a report on Thursday, June 27th. They issued a “buy” rating and a $6.00 price target for the company. Royal Bank of Canada lowered their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Finally, Morgan Stanley cut SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $10.00 to $5.00 in a research report on Wednesday, August 7th.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise grew its holdings in shares of SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after buying an additional 9,000 shares during the last quarter. Green Alpha Advisors LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth about $79,000. Federated Hermes Inc. grew its holdings in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after acquiring an additional 23,000 shares during the period. Moloney Securities Asset Management LLC raised its position in SOPHiA GENETICS by 111.4% during the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after acquiring an additional 93,800 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. lifted its holdings in SOPHiA GENETICS by 5.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock valued at $1,002,000 after acquiring an additional 9,700 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.